- Home
- LGCL vs AKTX Comparison
LGCL vs AKTX Comparison
Compare LGCL & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- AKTX
- Stock Information
- Founded
- LGCL 2009
- AKTX N/A
- Country
- LGCL China
- AKTX United States
- Employees
- LGCL N/A
- AKTX N/A
- Industry
- LGCL
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- AKTX Health Care
- Exchange
- LGCL NYSE
- AKTX Nasdaq
- Market Cap
- LGCL 47.7M
- AKTX 41.8M
- IPO Year
- LGCL 2024
- AKTX N/A
- Fundamental
- Price
- LGCL $0.96
- AKTX $1.17
- Analyst Decision
- LGCL
- AKTX
- Analyst Count
- LGCL 0
- AKTX 0
- Target Price
- LGCL N/A
- AKTX N/A
- AVG Volume (30 Days)
- LGCL 832.5K
- AKTX 28.8K
- Earning Date
- LGCL 01-01-0001
- AKTX 08-18-2025
- Dividend Yield
- LGCL N/A
- AKTX N/A
- EPS Growth
- LGCL N/A
- AKTX N/A
- EPS
- LGCL 0.07
- AKTX N/A
- Revenue
- LGCL $145,690,427.00
- AKTX N/A
- Revenue This Year
- LGCL N/A
- AKTX N/A
- Revenue Next Year
- LGCL N/A
- AKTX N/A
- P/E Ratio
- LGCL $18.10
- AKTX N/A
- Revenue Growth
- LGCL N/A
- AKTX N/A
- 52 Week Low
- LGCL $0.28
- AKTX $0.85
- 52 Week High
- LGCL $3.31
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- AKTX 44.98
- Support Level
- LGCL N/A
- AKTX $1.15
- Resistance Level
- LGCL N/A
- AKTX $1.22
- Average True Range (ATR)
- LGCL 0.00
- AKTX 0.08
- MACD
- LGCL 0.00
- AKTX -0.00
- Stochastic Oscillator
- LGCL 0.00
- AKTX 40.86
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.